Earnings summaries and quarterly performance for Zura Bio.
Executive leadership at Zura Bio.
Board of directors at Zura Bio.
Research analysts covering Zura Bio.
Recent press releases and 8-K filings for ZURA.
Zura Bio Reports Q3 2025 Financial Results and Clinical Trial Progress
ZURA
Earnings
Guidance Update
New Projects/Investments
- Zura Bio reported $139.0 million in cash and cash equivalents as of September 30, 2025, which is expected to fund planned operations through 2027.
- The company recorded a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025.
- Research and development expenses for Q3 2025 were $11.9 million, reflecting the continued advancement of the tibulizumab Phase 2 clinical trials.
- Zura Bio continued to advance its two Phase 2 clinical trials for tibulizumab (TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis), with topline data for both studies expected in the second half of 2026.
Nov 13, 2025, 11:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more